Literature DB >> 15629273

Cryosurgery in aggressive, benign, and low-grade malignant bone tumours.

René Veth1, Bart Schreuder, Herman van Beem, Maciej Pruszczynski, Jacky de Rooy.   

Abstract

Cryosurgery is a method of treatment for various tumours that induces tissue necrosis with ablative intent. It is used in benign, aggressive, and low-grade malignant bone tumours such as chondrosarcoma grade 1. We describe the history of the technique and the issues associated with cryobiology, as well as the indications, technique, complications, and results of cryosurgery. At the University Medical Centre Nijmegen, Netherlands, 302 tumours have been treated by use of cryosurgery with at least 2 years' follow-up. 96-100% of patients were cured-the response depended on tumour type. Comparison of functional results with data from studies shows that these results concur with other studies on cryosurgery, and are at least equal to results of marginal excision and mostly better than those of wide excisions of grade 1 chondrosarcomas. Thus from an oncological point of view, cryosurgery combined with intralesional excision is equal to marginal excision.

Entities:  

Mesh:

Year:  2005        PMID: 15629273     DOI: 10.1016/S1470-2045(04)01710-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  28 in total

1.  Cryosurgery/cryoablation in musculoskeletal neoplasms: history and state of the art.

Authors:  Peter S Rose; Jonathan M Morris
Journal:  Curr Rev Musculoskelet Med       Date:  2015-12

2.  Freezing Nitrogen Ethanol Composite May be a Viable Approach for Cryotherapy of Human Giant Cell Tumor of Bone.

Authors:  Po-Kuei Wu; Cheng-Fong Chen; Jir-You Wang; Paul Chih-Hsueh Chen; Ming-Chau Chang; Shih-Chieh Hung; Wei-Ming Chen
Journal:  Clin Orthop Relat Res       Date:  2017-02-14       Impact factor: 4.176

3.  What are the Oncologic and Functional Outcomes After Joint Salvage Resections for Juxtaarticular Osteosarcoma About the Knee?

Authors:  Jing Li; Zhen Wang; Chuanlei Ji; Guojing Chen; Dong Liu; Haodong Zhu
Journal:  Clin Orthop Relat Res       Date:  2017-04-19       Impact factor: 4.176

Review 4.  Technical and practical considerations for device selection in locoregional ablative therapy.

Authors:  Sean P Zivin; Ron C Gaba
Journal:  Semin Intervent Radiol       Date:  2014-06       Impact factor: 1.513

5.  Curettage and cryosurgery for low-grade cartilage tumors is associated with low recurrence and high function.

Authors:  David G Mohler; Richard Chiu; David A McCall; Raffi S Avedian
Journal:  Clin Orthop Relat Res       Date:  2010-06-24       Impact factor: 4.176

6.  Use of refrigerant spray of a propane/butane/isobutane gas mixture in the management of keratocystic odontogenic tumors: a preliminary study.

Authors:  Eduardo Luis de Souza Cruz; Ana Karla da Silva Tabosa; Aline Semblano Carreira Falcão; Talita Tartari; Lucas Machado de Menezes; Edmar Tavares da Costa; José Thiers Carneiro Júnior
Journal:  Oral Maxillofac Surg       Date:  2016-11-21

7.  Intralesional treatment versus wide resection for central low-grade chondrosarcoma of the long bones.

Authors:  Edwin F Dierselhuis; Krista A Goulding; Martin Stevens; Paul C Jutte
Journal:  Cochrane Database Syst Rev       Date:  2019-03-07

8.  Extended intralesional treatment versus resection of low-grade chondrosarcomas.

Authors:  Chad Aarons; Benjamin K Potter; Sheila C Adams; J David Pitcher; H Thomas Temple
Journal:  Clin Orthop Relat Res       Date:  2009-01-14       Impact factor: 4.176

9.  Grade I chondrosarcoma of bone: the Münster experience.

Authors:  Arne Streitbürger; Helmut Ahrens; Maurice Balke; Horst Buerger; Winfried Winkelmann; Georg Gosheger; Jendrik Hardes
Journal:  J Cancer Res Clin Oncol       Date:  2008-10-15       Impact factor: 4.553

10.  Reimplantation of the resected tumour-bearing segment after recycling using liquid nitrogen for osteosarcoma.

Authors:  Mohamed Abdel Rahman; Ayman Bassiony; Hisham Shalaby
Journal:  Int Orthop       Date:  2009-04-16       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.